Oxford Asset Management’s Evommune Inc EVMN Stock Holding History

Oxford Asset Management’s Portfolio EVMN Stock Details EVMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,565	Closed	-$335K	–	763
2025 Q4	$335K	Buy	+19,565	New	+$368K	0.12%	266

Other funds holding EVMN

EQT Fund Management Luxembourg $1.02B AUM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Andera Partners Paris $206M AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

JP Morgan Chase

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Oxford Asset Management's EVMN Position: Q1 2026 in Review

Oxford Asset Management sold out of Evommune Inc (EVMN) in Q1 2026, closing a stake of 19,565 shares — an estimated $335K sold.

Oxford Asset Management first reported a position in EVMN in Q4 2025 and held it in 1 quarter. The position peaked at $335K in Q4 2025. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

Oxford Asset Management reported no remaining Evommune Inc position as of Q1 2026 after selling out during the quarter.
Oxford Asset Management sold 19,565 Evommune Inc shares in Q1 2026, an estimated $335K.
Oxford Asset Management first reported a position in Evommune Inc in Q4 2025 and held it in 1 quarter.
Oxford Asset Management's Evommune Inc position peaked at $335K in Q4 2025.
84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.